Drug Trial Radar · NCT07640295
Study of JAB-23E73 in Combination With Chemotherapy in Participants With Metastatic PDAC Harboring KRAS Gene Alterations
Last checked: Nov 20, 2026Latest source record: Aug 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
80
Planned (sponsor's estimate)
Start
Jul 16, 2026
Primary completion
Dec 31, 2029
Study completion Dec 31, 2030
Sponsor
- Lead sponsor
- Jacobio Pharmaceuticals Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jun 10, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to determine the safety and efficacy of pan KRAS inhibitor JAB-23E73 in combination with nab-paclitaxel and gemcitabine in participants with metastatic PDAC harboring KRAS gene alterations.
Conditions
- Metastatic Pancreatic Ductal Adenocarcinoma
Interventions
JAB-23E73 tablet,nab-paclitaxel,gemcitabineDrug
Orally, intravenous (IV) infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Dose limiting toxicities (DLT)Time frame: Up to 28 days
- Adverse events.safety evaluationTime frame: Up to approximately 3 years
Locations
13 sites in 1 country. Site status is shown where the registry gives one.
Beijing Tsinghua Changgung Hospital
Beijing, China · Recruiting
Hunan Cancer Hospital
Changsha, China · Not yet recruiting
Harbin Medical University Cancer Hospital
Harbin, China · Not yet recruiting
Jiangsu Province Hospital
Nanjing, China · Not yet recruiting
Shanghai Jiaotong University School of Medicine Ruijin Hospital
Shanghai, China · Recruiting
ShanXi Cancer Hospital
Taiyuan, China · Recruiting
Hubei Province Hospital
Wuhan, China · Not yet recruiting
Wuhan Union Hospital Of China
Wuhan, China · Recruiting
Zhongnan Hospital of Wuhan University
Wuhan, China · Recruiting
Henan Cancer Hospital
Zhengzhou, China · Not yet recruiting
The First Affiliated hospital of Zhengzhou University
Zhengzhou, China · Not yet recruiting
Beijing Cancer Hospital
Beijing, Beijing Municipality, China · Recruiting
Zhejiang Cancer Hospital
Hangzhou, Zhejiang, China · Not yet recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.